The triple negative breast cancer (TNBC) subtype represents approximately 15% to 20% of breast cancers and comprises a heterogeneous group of tumors phenotypically characterized by a lack of expression of estrogen and progesterone receptors and no amplification of HER2 [2,3]. This evidence concerns the gene ERBB2 and breast cancer.